Innovative Research

Spirogene has embarked on an intensive research programme to develop Aspire, its flagship vaccine product-line and SpiroChek, an ELISA-based serological diagnostic for both swine dysentery and avian intestinal spirochaetosis. Using a reverse vaccinology approach integrating bioinformatics, genomics and proteomics, Spirogene has rapidly identified an array of unique and novel candidates for both vaccine and diagnostic applications.

Spirogene is now conducting proof-of-concept trials to assess the efficacy of its vaccine and diagnostic candidates in animal models challenged with AIS and Swine Dysentery.

Figure 1.2: Spirogene's vaccine and diagnostic development pathway showing the interplay between the different elements of reverse vaccinology (Mohavedi and Hampson, 2008).